▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #1266 by analyst upside · 2026-11-12
AXSM
Axsome Therapeutics, Inc.
Healthcare · Market Cap $8B · P/E 0x
ANALYST PRICE TARGET
+78.1%
implied upside to consensus target
Current Price $149.24
Consensus Target $265.86
Bull Target $315.0
Bear Target $220.0
Analysts Covering 21
ANALYST CONSENSUS - BUY
Strong Buy
3
Buy
17
Hold
1
Sell
0
52-Week Low $123.0
52-Week High $260.19
YTD Return -16.5%
FUNDAMENTALS
Market Cap $8B
P/E Ratio (TTM) N/A
Forward P/E 44.1x
EPS (TTM) $-3.21
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $865M
Profit Margin -18.2%
52-WEEK RANGE
52-Week Low $123.0
52-Week High $260.19
Current Price $149.24
Bear Target $220.0
Bull Target $315.0
● Now $149.24 ● Target $265.86
TRADING DATA
Avg Volume 844K
YTD Return -16.5%
Analyst Count 21
Consensus Buy
Upside to Target +78.1%
Last Updated 2026-11-12

ANALYST SUMMARY

Axsome Therapeutics, Inc. (AXSM) is currently trading at $149.24 with a Wall Street consensus price target of $265.86, implying potential upside of 78.1% over the next 12 months. 21 analysts currently cover AXSM, with a consensus rating of Buy - 95% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $315.0, while the most cautious has a target of $220.0.

AXSM operates in the Healthcare sector with a market capitalisation of $8B. The stock is down 16.5% year-to-date and is currently trading near the lower end of its 52-week range of $123.0 – $260.19.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for AXSM, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Mizuho - Reiterated
Outperform → Outperform 2026-11-04 Building track record
Morgan Stanley - Reiterated
Equal-Weight → Equal-Weight 2026-11-03 Building track record
UBS - Reiterated
Buy → Buy 2026-11-03 33% win rate (6 calls)
RBC Capital - Reiterated
Outperform → Outperform 2026-11-03 Building track record
Guggenheim - Reiterated
Buy → Buy 2026-11-03 62% win rate (8 calls)
Baird - Reiterated
Outperform → Outperform 2026-11-03 Building track record
Piper Sandler - Reiterated
Overweight → Overweight 2026-10-26 14% win rate (7 calls)
RBC Capital - Reiterated
Outperform → Outperform 2026-10-08 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
63
out of 100
Coverage depth
24/30
Consensus clarity
17/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →